Professor Anderson is a Principal Research Fellow at QIMR Berghofer where he heads the Iron Metabolism Laboratory and Chronic Disorders Program. He is the immediate past Deputy Director of the Institute. He is an Adjunct Professor in the School of Chemistry and Molecular Biosciences at the University of Queensland and a Visiting Professor at the National Center for Nanoscience and Technology in Beijing.
After undergraduate studies at the University of Newcastle and an MSc at McMaster University in Canada, Professor Anderson completed a PhD at the University of Queensland followed by postdoctoral work at the US National Institutes of Health. He has worked in the area of iron homeostasis for over 30 years and has other research interests in gastrointestinal and liver disease, and nanotechnology-based drug delivery platforms. His particular areas of focus include mechanisms of intestinal iron absorption and its regulation, the pathogenesis of iron loading diseases, the use of nanotechnology for modulating body iron levels and for cancer therapy, iron homeostasis in pregnancy and early postnatal life and mechanisms of hepatic encephalopathy. He is a former President of the International BioIron Society, serves on the Board of the International Biometals Society and has served on the Council of the Australian Society for Biochemistry and Molecular Biology.
The Iron Metabolism Laboratory focuses on understanding the homeostasis of the essential trace element iron (and related metals), the natural history of iron-related disorders and potential therapies for treating them, and mechanisms of liver disease.
Current research activities include:
elucidating the basic mechanisms of intestinal iron absorption and its regulation. Increased absorption characterises most iron loading disorders such as haemochromatosis and thalassaemia. Emphasis is being placed on the ferroportin/hephaestin iron transport complex and its modulation by the iron regulatory peptide hepcidin
exploring novel mechanisms of regulating iron intake in pregnancy and early postnatal life. These are times of high iron demand and this work has significant implications for maternal health as well as infant nutrition and complementary feeding
using novel nanoparticle technology to develop better methods for delivering iron removing agents. Target tissues for iron removal include the liver, brain and heart, as well as tumours
studying the natural history of the iron loading disorder hereditary haemochromatosis and exploring markers for monitoring the effectiveness of treatment
examining the mechanisms underlying hepatic encephalopathy, the neurophsychiatric syndrome that often accompanies severe liver disease. Our work takes a broad approach from basic molecular mechanisms to clinical applications
RESEARCH HIGHLIGHTS
cloning and analysis of the iron oxidase hephaestin. Hephaestin plays an important role in the efficient intestinal absorption or iron and its identification represented a major advance in our understanding of the molecular basis of intestinal iron transport
demonstrating hephaestin plays an important role in controlling iron levels in extra-intestinal tissues, notably the central nervous system, heart and kidney
demonstrating expression of the iron regulatory hormone hepcidin is defective in HFE-associated haemochromatosis, revealing hepcidin is a downstream target of HFE and not an upstream modulator as was previously proposed. This led to a paradigm shift in the field and provided a mechanistic basis for understanding the pathogenesis of primary iron loading disorders
demonstrating a close inverse relationship between the expression of hepcidin in the liver and iron transport molecules in the small intestine. These studies confirmed hepcidin as the key systemic regulator of intestinal iron absorption
showing diferric transferrin can act as a key regulator of hepcidin, thereby providing an important link between body iron levels and the regulator of iron transport into the plasma
undertaking a large population-based study which has provided the most objective evidence to date of disease penetrance in HFE-related haemochromatosis
providing a molecular explanation for the mucosal block phenomenon which can decrease the efficiency of intestinal iron absorption
defining mechanisms of intestinal iron absorption and its regulation during early infancy
providing definitive evidence that the transferrin/transferrin receptor system does not play a direct role in intestinal iron absorption, but an indirect role in absorption by supplying iron to the proliferating cells of the intestinal crypts
PROFESSIONAL MEMBERSHIPS
American Gastroenterological Association
Australian Society of Biochemistry and Molecular Biology
Gastroenterological Society of Australia
International Bioiron Society
International Biometals Society
AWARDS RECOGNITION
2011-2017
President-Elect, President, then Past-President of the International BioIron Society
2004-2016
NHMRC Senior Research Fellowship
1994
Silver Seahorse Award, Distinguished graduate award, Department of Biological Sciences, University of Newcastle
1993-1995
AMRAD Postdoctoral Award
1993
Career Development Award, ASTRA/Gastroenterological Society of Australia Research Institute
1992
Young Investigator Award, Gastroenterological Society of Queensland
1990-1994
J. Martin Postdoctoral Fellowship, National Health and Medical Research Council of Australia
1990-1992
Fulbright Postdoctoral Fellowship, Australian-American Educational Foundation
1989
Queensland Medical Research Award, Australian Society for Medical Research
Marcel Simon Prize, Young investigator at the IX International Conference on Proteins of Iron Transport and Storage
1980
University Medal, University of Newcastle
EDUCATIONAL BACKGROUND
1986-1990: PhD, University of Queensland, ‘Studies of the transferrin receptor and its role in iron absorption’
1981-1983: MSc, McMaster University, Canada, ‘The mutagenicity, metabolism and macromolecule binding of the nitrated polycyclic aromatic hydrocarbon 3-nitroperylene’